CP and cancer: Inhibition of proteasome CT-L activity was initially pursued as a therapeutic strategy for the treatment of cancers with highly proliferative and proteasome-dependent cells; however, current FDA-approved proteasome inhibitors lack selectivity between the cP and iP (Kisselev et al., 2012; Adams, 2004).